Idexx Laboratories (IDXX)
NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
$555.67-2.56%
Close 2026-07-08 · 1-day change
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-08
Reading IDXX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track IDXX free→QuarterlyIQ Insights · IDXX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenues | 4,446.1 | 4,303.7 | 3,897.5 | 3,661.0 | 3,367.3 | 3,215.4 | 2,706.7 | 2,406.9 | 1,775.4 | 1,775.4 | 1,775.4 | 1,601.9 | 1,293.3 | 1,293.3 | 1,293.3 | 1,218.7 | 1,024.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 1,775.4 | 1,775.4 | 1,601.9 | 1,293.3 | 1,293.3 | 1,293.3 | 1,218.7 | 1,024.0 |
| Cost of Revenues | 1,687.2 | 1,644.1 | 1,518.6 | 1,471.0 | 1,363.0 | 1,325.9 | 1,135.6 | 1,041.4 | 800.0 | 800.0 | 800.0 | 711.6 | 594.2 | 594.2 | 594.2 | 572.2 | 494.3 |
| Gross Profit | 2,758.9 | 2,659.6 | 2,378.9 | 2,190.0 | 2,004.3 | 1,889.4 | 1,571.0 | 1,365.5 | 975.4 | 975.4 | 975.4 | 890.3 | 699.1 | 699.1 | 699.1 | 646.5 | 529.8 |
| Operating Expenses & Income | |||||||||||||||||
| R&D Expenses | 257.9 | 251.2 | 219.8 | 191.0 | 254.8 | 161.0 | 141.2 | 133.2 | 101.1 | 101.1 | 101.1 | 99.7 | 82.0 | 82.0 | 82.0 | 76.0 | 70.7 |
| Operating Income | 1,406.1 | 1,360.0 | 1,128.3 | 1,097.1 | 898.8 | 932.0 | 694.5 | 552.8 | 350.2 | 350.2 | 350.2 | 299.9 | 262.6 | 262.6 | 262.6 | 236.2 | 172.5 |
| Earnings from Continuing Operations | |||||||||||||||||
| Interest Expense | — | — | — | 41.6 | 39.9 | 29.8 | 33.1 | 31.1 | 32.0 | 32.0 | 32.0 | 29.2 | 3.8 | 3.8 | 3.8 | 3.5 | 4.6 |
| Asset Writedown | — | — | 0.3 | 1.5 | 2.3 | 5.1 | 2.5 | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 1,369.5 | 1,324.2 | 1,109.8 | 1,061.2 | 860.0 | 902.7 | 662.0 | 522.2 | 321.8 | 321.8 | 321.8 | 273.1 | 260.6 | 260.6 | 260.6 | 234.4 | 170.2 |
| Income Tax Expense | 274.3 | 264.7 | 222.0 | 216.1 | 180.9 | 157.8 | 79.9 | 94.4 | 99.8 | 99.8 | 99.8 | 81.0 | 82.3 | 82.3 | 82.3 | 72.7 | 54.0 |
| Net Income | |||||||||||||||||
| Minority Interest | — | — | — | 0.0 | 0.0 | (0.0) | 0.4 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | (0.0) | 0.0 |
| Net Income | 1,095.2 | 1,059.5 | 887.9 | 845.0 | 679.1 | 744.8 | 581.8 | 427.7 | 222.0 | 222.0 | 222.0 | 192.1 | 178.3 | 178.3 | 178.3 | 161.8 | 116.2 |
| Per Share | |||||||||||||||||
| Basic EPS | 13.75 | 13.17 | 10.77 | 10.17 | 8.12 | 8.74 | 6.82 | 4.97 | 2.47 | 2.47 | 2.47 | 2.07 | 3.24 | 3.24 | 3.24 | 2.85 | 1.94 |
| Diluted EPS | 13.66 | 13.08 | 10.67 | 10.06 | 8.03 | 8.60 | 6.71 | 4.89 | 2.44 | 2.44 | 2.44 | 2.05 | 3.17 | 3.17 | 3.17 | 2.78 | 1.87 |
| Revenue per Share | 55.46 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 79.6 | 80.4 | 82.5 | 83.1 | 83.6 | 85.2 | 85.3 | 86.1 | 89.7 | 89.7 | 89.7 | 92.6 | 55.0 | 55.0 | 55.0 | 56.8 | 60.0 |
| Diluted Weighted Avg Shares | 80.2 | 81.0 | 83.2 | 84.0 | 84.6 | 86.6 | 86.7 | 87.5 | 90.9 | 90.9 | 90.9 | 93.6 | 56.2 | 56.2 | 56.2 | 58.2 | 62.2 |
| Supplemental | |||||||||||||||||
| EBITDA | — | 1,505.2 | 1,258.3 | 1,212.0 | 1,010.7 | 1,036.6 | 790.5 | 640.9 | 428.5 | 428.5 | 428.5 | 368.9 | 315.0 | 315.0 | 315.0 | 284.4 | 220.4 |
| EBIT | 1,406.1 | 1,360.0 | 1,128.3 | 1,097.1 | 898.8 | 932.0 | 694.5 | 552.8 | 350.2 | 350.2 | 350.2 | 299.9 | 262.6 | 262.6 | 262.6 | 236.2 | 172.5 |
| Effective Tax Rate | 20.0% | 20.0% | 20.0% | 20.4% | 21.0% | 17.5% | 12.1% | 18.1% | 31.0% | 31.0% | 31.0% | 29.7% | 31.6% | 31.6% | 31.6% | 31.0% | 31.7% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.